Search results for " PEG IFN"

showing 3 items of 3 documents

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.

2012

Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naïve patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800–1400 mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44.2% of Peg-…

AdultMaleAdolescentInterferon alpha-2Antiviral AgentsPolyethylene GlycolsYoung AdultSex FactorsRibaviringenderHumansAgedSettore MED/12 - GastroenterologiaPeg IFNAge FactorsInterferon-alphaHepatitis C ChronicMiddle Agedcentral fat distribution cytokines metabolic syndrome pharmacokinetics sustained virological responseRecombinant ProteinsTreatment OutcomeDrug Therapy CombinationFemaleEpatite HCV; Peg IFN; genderMenopauseSettore SECS-S/01 - StatisticaEpatite HCVJournal of viral hepatitis
researchProduct

LIVER RELATED EVENTS AND SURVIVAL IN PATIENTS WITH COMPENSATED HCV CIRRHOSIS: THE ROLE OF SUSTAINED VIROLOGICAL RESPONSE TO PEG-IFN BASED THERAPY AND…

2011

HCV Cirrhosis SVR PEG IFN PORTAL HYPERTENSION
researchProduct

Risk of disease decompensation and HCC in patients with HCV cirrhosis non responders to PEG IFN plus RBV

2012

HCV HCC PEG IFN RBV
researchProduct